Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis

Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 012 India. Reaching People. Touching Lives FOR IMMEDIATE RELEASE Sun Pharma Announces China NMPA Approval for ILUMETRI (Tildrakizumab Injection) For Treatment of Adults with Moderate-To-Severe Plaque Psoriasis • CMS is Sun Pharma’s exclusive commercial partner for ILUMETRI in Greater China region • In China clinical studies, the PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52 Mumbai, May 30, 2023: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomb : SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) announced that the New Drug Application (NDA) of tildrakizumab injection under the brand name of ILUMETRI has been approved by the National Medic al Products Administration of the People’s Republic of China (“China”) (NMPA). ILUMETRI is indicated for the treatment of adults with moderate -to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In June 2019, Sun Pharma out -licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for development, regulatory filings and commercialisation of the product in Greater China. According to CMS, t he results of the extended study of Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance1. T ildrakizumab Injection has also been approved for marketing in the U S, EU, Japan, UK, Switzerland, Canada, Australia, Hong Kong and other countries/regions under the brands of ILUMYA and ILUMETRI in different geographies. About ILUMETRI ILUMETRI is a humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL- 23. With this precise targeting, ILUMETRI has the potential to help control the pathogenic cells responsible for the inflammatory process of psoriasis with limited impact on the rest of the immune system. About Plaque Psoriasis Psoriasis is a chronic immune disease that appears on the skin. It affects approximately 125 million people worldwide 2. It is a noncontagious disorder that accelerates the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful and can crack and bleed. Despite different treatment options existing, Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 012 India. Reaching People. Touching Lives many people with plaque psoriasis continue to struggle with the ongoing, persistent nature of this chronic disease. References 1. CMS Press Release dated 30 May 2023 2. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082 About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generic pharmaceutical company and India's top p harmaceutical company. A vertically integrated business and a skilled team enables it to deliver high -quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manu facturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi -cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live. Contacts: Sun Pharma Investors Dr. Abhishek Sharma Media Gaurav Chugh Tel +91 22 4324 4324, Xtn 2929 Tel +91 22 4324 4324, Xtn 5373 Tel (D) +91 22 4324 2929 Tel (D) +91 22 4324 5373 Mobile +91 98196 86016 Mobile +91 98104 71414 E mail [email protected] E mail [email protected]

The release as fetched from its publisher. sunpharma.com ↗